Biomarker of Diabetic Retinopathy
Part of paid clinical trials in Carmel, Indiana.
- Sponsor
- Indiana University
- Study ID
- NCT05079399
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Blood draw — OTHERBlood samples will be collected via venipuncture
Study Details
Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.
Key Dates
- Start date
- Jan 1, 2022
- Status verified
- Mar 2025
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 192 participants (estimated)
Arms
- Arm: Healthy Control
- Arm: Diabetes but no retinopathy
- Arm: Mild non proliferative diabetic retinopathy
- Arm: Moderate non proliferative diabetic retinopathy
- Arm: Severe non proliferative diabetic retinopathy
- Arm: Proliferative diabetic retinopathy
Primary Outcome Measure
mRNA and miRNA sequencing of circulating angiogenic cells isolated from study participants [ Time Frame: Baseline and change in RNA signature in follow up visit (between 3-5 years) ]
Central Contacts
- Ashay D Bhatwadekar, PhD, RPh3172785075
- Amir R Hajrasouliha, MD3179441154
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Spring Mill Clinic | Carmel | Indiana | 46920 | Amir R Hajrasouliha, MD |
| Eskenazi Eye Clinic | Indianapolis | Indiana | 46202 | Amir R Hajrasouliha, MD |
| Glick Eye Institute | Indianapolis | Indiana | 46202 |
Find similar trials in Carmel, IN
Related Studies
- Fenofibrate for Prevention of DR WorseningPHASE3 · Recruiting · Jaeb Center for Health Research · Glendale, California
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Clinical Applications of Advanced Ophthalmic ImagingRecruiting · University of Miami · Miami, Florida
- Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)Recruiting · University of Alabama at Birmingham · Birmingham, Alabama